Mladsi DM, Barnett CL, Kaye JA. Identification of potential bias from data sources and study designs used to estimate platelet transfusion adverse event rates. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Assimon MM, Brookhart MA, Fine JP, Heiss G, Layton JB, Flythe JE. A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis. Am J Kidney Dis. 2018 Sep;72(3):337-48. doi: 10.1053/j.ajkd.2018.02.350.
Barnett CL, Mladsi D, Vredenburg M, Aggarwal K. Cost estimate of platelet transfusion in the United States for patients with chronic liver disease and associated thrombocytopenia undergoing elective procedures. J Med Econ. 2018 Aug;21(8):827-34. doi: 10.1080/13696998.2018.1490301
Lynen R, Taylor TN, Farkouh RA, Candrilli SD, Graham J, Colligs A. The effect of age, race, and folic acid-containing supplements on red blood cell folate levels among United States women of child bearing age. Poster presented at the ASRM Annual Meeting; October 26, 2010. [abstract] Fertil Steril. 2010 Sep; 94(4, Suppl 1):S93. doi: 10.1016/j.fertnstert.2010.07.392
Roskell N, Wolowacz S, Christiansen AV, Plumb JM. Are double-blind, double-dummy studies suitable for resource utilisation analyses? An example from a new oral anticoagulant for the prevention of venous thromboembolism (VTE) following orthopaedic surgery. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A167.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the preventionof venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost. 2010 Feb 1;103(2):360-71.
Zaniolo O, Wolowacz SE, Pradelli L. Economic performance of dabigatran etexilate for primary VTE prevention following total hip and knee replacement surgery in Italy [Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia]. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.
Zaniolo O, Wolowacz SE, Pradelli L. Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.